The FDA's move to incorporate Bayesian statistical methods into clinical trials of drugs and biologics garnered special treatment in JAMA this week. JAMA published three perspectives -- two welcoming ...
To address the limitations of binary pCR classification, Pusztai and colleagues developed the residual cancer burden (RCB) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results